Fidaxomicin versus oral vancomycin for Clostridioides difficile infection among patients at high risk for recurrence based on real-world experience
Infection Control & Hospital Epidemiology · 2024
DOI: 10.1017/ice.2024.145 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Infection Control & Hospital Epidemiology, 2024. Verfasst von Natasha N Pettit und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Chicago Medicine, Chicago, IL, USA. Hauptthemen laut MEDLINE: Fidaxomicin, Vancomycin, Clostridium Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Clostridioides difficile infection (CDI) is a common nosocomial infection and is associated with a high healthcare burden due to high rates of recurrence. In 2021 the IDSA/SHEA guideline update recommended fidaxomicin (FDX) as first-line therapy. Our medical center updated our institutional guidelines to follow these recommendations, prioritizing FDX use among patients at high risk for recurrent CDI (rCDI).
Methods
This pre- post- quasi-experimental study included patients with a presumptive diagnosis of CDI at risk for recurrence (age >/= 65 years, immunocompromised, severe CDI) that received vancomycin (VAN) or FDX between October 2019 to October 2022. Patients who received bezlotoxumab, had fulminant CDI, or received
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Chicago Medicine, Chicago, IL, USA.
- Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago Medicine, Chicago, IL, USA.
ORCID-Profile: Natasha N Pettit, Alison K Lew, Elizabeth Bell, Christopher J Lehmann, Jennifer Pisano
Zitieren
APA
Pettit, N. N., Lew, A. K., Nguyen, C. T., Bell, E., Lehmann, C. J., & Pisano, J. (2024). Fidaxomicin versus oral vancomycin for Clostridioides difficile infection among patients at high risk for recurrence based on real-world experience. Infection Control & Hospital Epidemiology. https://doi.org/10.1017/ice.2024.145
Vancouver
Pettit NN, Lew AK, Nguyen CT, Bell E, Lehmann CJ, Pisano J. Fidaxomicin versus oral vancomycin for Clostridioides difficile infection among patients at high risk for recurrence based on real-world experience. Infection Control & Hospital Epidemiology. 2024. doi:10.1017/ice.2024.145
BibTeX
@article{Pettit2024,
author = {Pettit, Natasha N and Lew, Alison K and Nguyen, Cynthia T and Bell, Elizabeth and Lehmann, Christopher J and Pisano, Jennifer},
title = {Fidaxomicin versus oral vancomycin for Clostridioides difficile infection among patients at high risk for recurrence based on real-world experience},
journal = {Infection Control & Hospital Epidemiology},
year = {2024},
doi = {10.1017/ice.2024.145}
}
EUVIMED